CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Prelude Therapeutics Incorporated - PRLD CFD

4.70
1.05%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.19
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Prelude Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 4.75
Open* 4.65
1-Year Change* -25%
Day's Range* 4.65 - 4.81
52 wk Range 1.66-8.57
Average Volume (10 days) 57.84K
Average Volume (3 months) 4.43M
Market Cap 186.96M
P/E Ratio -100.00K
Shares Outstanding 109.64M
Revenue N/A
EPS -2.17
Dividend (Yield %) N/A
Beta 1.41
Next Earnings Date Mar 13, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 28, 2024 4.70 0.05 1.08% 4.65 4.83 4.65
Mar 27, 2024 4.75 0.23 5.09% 4.52 4.80 4.52
Mar 26, 2024 4.59 0.09 2.00% 4.50 4.71 4.48
Mar 25, 2024 4.59 0.00 0.00% 4.59 4.81 4.45
Mar 22, 2024 4.66 -0.04 -0.85% 4.70 4.85 4.60
Mar 21, 2024 4.82 0.00 0.00% 4.82 4.96 4.71
Mar 20, 2024 4.82 0.12 2.55% 4.70 4.90 4.64
Mar 19, 2024 4.78 0.14 3.02% 4.64 4.90 4.41
Mar 18, 2024 4.63 0.03 0.65% 4.60 4.89 4.59
Mar 15, 2024 4.69 0.43 10.09% 4.26 4.69 4.18
Mar 14, 2024 4.42 -0.08 -1.78% 4.50 4.55 4.31
Mar 13, 2024 4.59 0.47 11.41% 4.12 4.61 4.12
Mar 12, 2024 4.07 0.09 2.26% 3.98 4.14 3.86
Mar 11, 2024 4.07 -0.16 -3.78% 4.23 4.24 4.07
Mar 8, 2024 4.32 0.08 1.89% 4.24 4.38 4.24
Mar 7, 2024 4.31 0.23 5.64% 4.08 4.31 4.08
Mar 6, 2024 4.09 -0.02 -0.49% 4.11 4.39 3.90
Mar 5, 2024 4.09 -0.05 -1.21% 4.14 4.22 4.05
Mar 4, 2024 4.20 -0.39 -8.50% 4.59 4.59 4.07
Mar 1, 2024 4.55 0.44 10.71% 4.11 4.55 4.04

Prelude Therapeutics Incorporated Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Prelude Therapeutics Inc Earnings Release
Q1 2024 Prelude Therapeutics Inc Earnings Release

Forecast

-

Previous

-
Friday, June 14, 2024

Time (UTC)

17:00

Country

US

Event

Prelude Therapeutics Inc Annual Shareholders Meeting
Prelude Therapeutics Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 123.54 113.735 58.763 28.109 14.975
Selling/General/Admin. Expenses, Total 30.651 26.957 10.586 3.83 2.354
Research & Development 92.889 86.778 48.177 24.279 12.621
Operating Income -123.54 -113.735 -58.763 -28.109 -14.975
Other, Net 8.102 2.041 1.834 0.539 0.295
Net Income Before Taxes -115.438 -111.694 -56.929 -27.57 -14.68
Net Income After Taxes -115.438 -111.694 -56.929 -27.57 -14.68
Net Income Before Extra. Items -115.438 -111.694 -56.929 -27.57 -14.68
Net Income -115.438 -111.694 -56.929 -27.57 -14.68
Income Available to Common Excl. Extra. Items -115.438 -111.694 -56.929 -27.57 -14.68
Income Available to Common Incl. Extra. Items -115.438 -111.694 -56.929 -27.57 -14.68
Diluted Net Income -115.438 -111.694 -56.929 -27.57 -14.68
Diluted Weighted Average Shares 47.3716 46.0498 12.4785 4.27042 4.27042
Diluted EPS Excluding Extraordinary Items -2.43686 -2.42551 -4.56218 -6.45603 -3.4376
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -2.43686 -2.42551 -4.56218 -6.45603 -3.4376
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 32.398 29.115 33.385 30.406 29.461
Selling/General/Admin. Expenses, Total 7.432 7.281 7.516 7.517 8.151
Research & Development 24.966 21.834 25.869 22.889 21.31
Operating Income -32.398 -29.115 -33.385 -30.406 -29.461
Other, Net 1.967 1.397 4.744 0.448 2.087
Net Income Before Taxes -30.431 -27.718 -28.641 -29.958 -27.374
Net Income After Taxes -30.431 -27.718 -28.641 -29.958 -27.374
Net Income Before Extra. Items -30.431 -27.718 -28.641 -29.958 -27.374
Net Income -30.431 -27.718 -28.641 -29.958 -27.374
Income Available to Common Excl. Extra. Items -30.431 -27.718 -28.641 -29.958 -27.374
Income Available to Common Incl. Extra. Items -30.431 -27.718 -28.641 -29.958 -27.374
Diluted Net Income -30.431 -27.718 -28.641 -29.958 -27.374
Diluted Weighted Average Shares 56.2405 47.7372 47.6892 47.4498 47.2767
Diluted EPS Excluding Extraordinary Items -0.54109 -0.58064 -0.60058 -0.63136 -0.57902
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.54109 -0.58064 -0.60058 -0.63136 -0.57902
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 204.38 295.115 220.809 20.224 15.595
Cash and Short Term Investments 201.728 291.233 218.309 18.879 15.595
Cash & Equivalents 30.605 31.828 218.309 18.879 15.595
Prepaid Expenses 2.652 3.882 2.5 1.345 0
Total Assets 220.5 305.098 223.59 21.871 16.406
Property/Plant/Equipment, Total - Net 6.7 5.636 2.48 1.647 0.811
Property/Plant/Equipment, Total - Gross 10.019 7.634 3.563 2.203 1.002
Accumulated Depreciation, Total -3.319 -1.998 -1.083 -0.556 -0.191
Total Current Liabilities 21.702 19.201 11.375 4.835 2.447
Accounts Payable 6.777 7.84 3.92 1.974 1.362
Accrued Expenses 14.401 11.274 7.035 2.289 1.026
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0 0.258 0
Other Current Liabilities, Total 0.524 0.087 0.42 0.314 0.059
Total Liabilities 25.063 19.201 11.407 4.84 2.504
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 3.361 0 0.032 0.005 0.057
Total Equity 195.437 285.897 212.183 17.031 13.902
Redeemable Preferred Stock 0 66.443 36.595
Common Stock 0.005 0.005 0.004 0 0
Additional Paid-In Capital 531.682 505.723 319.605 1.085 0.234
Retained Earnings (Accumulated Deficit) -334.558 -219.12 -107.426 -50.497 -22.927
Total Liabilities & Shareholders’ Equity 220.5 305.098 223.59 21.871 16.406
Total Common Shares Outstanding 47.899 47.6023 43.7057 4.27042 4.27042
Other Long Term Assets, Total 9.42 4.347 0.301
Short Term Investments 171.123 259.405
Other Equity, Total -1.692 -0.711
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 234.916 260.21 175.263 204.38 226.893
Cash and Short Term Investments 230.506 254.989 172.255 201.728 224.043
Cash & Equivalents 15.896 26.446 18.201 30.605 52.022
Prepaid Expenses 4.41 5.221 3.008 2.652 2.85
Total Assets 258.511 280.611 198.32 220.5 242.327
Property/Plant/Equipment, Total - Net 7.082 7 6.731 6.7 6.464
Other Long Term Assets, Total 16.513 13.401 16.326 9.42 8.97
Total Current Liabilities 16.893 15.19 19.662 21.702 21.56
Accounts Payable 5.17 5.585 7.082 6.777 10.25
Accrued Expenses 10.904 8.796 11.692 14.401 11.135
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 0.819 0.809 0.888 0.524 0.175
Total Liabilities 20.254 18.551 23.023 25.063 24.92
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 3.361 3.361 3.361 3.361 3.36
Total Equity 238.257 262.06 175.297 195.437 217.407
Common Stock 0.005 0.005 0.005 0.005 0.005
Additional Paid-In Capital 662.172 655.473 537.966 531.682 525.682
Retained Earnings (Accumulated Deficit) -423.315 -392.707 -362.276 -334.558 -305.917
Total Liabilities & Shareholders’ Equity 258.511 280.611 198.32 220.5 242.327
Total Common Shares Outstanding 54.8157 54.8087 47.9163 47.899 47.8468
Short Term Investments 214.61 228.543 154.054 171.123 172.021
Other Equity, Total -0.605 -0.711 -0.398 -1.692 -2.363
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -115.438 -111.694 -56.929 -27.57 -14.68
Cash From Operating Activities -83.729 -83.531 -46.177 -25.665 -12.954
Cash From Operating Activities 1.324 0.915 0.542 0.382 0.149
Non-Cash Items 29.453 23.623 5.594 0.856 0.195
Changes in Working Capital 0.932 3.625 4.616 0.667 1.382
Cash From Investing Activities 81.691 -263.803 -0.621 -0.78 -0.529
Capital Expenditures -3.019 -2.323 -0.621 -0.78 -0.529
Cash From Financing Activities 0.815 164.897 246.228 29.729 17.937
Issuance (Retirement) of Stock, Net 0.815 165.2 246.498 29.853 17.937
Issuance (Retirement) of Debt, Net -0.258 -0.124 0
Net Change in Cash -1.223 -182.437 199.43 3.284 4.454
Financing Cash Flow Items 0 -0.303 -0.012
Other Investing Cash Flow Items, Total 84.71 -261.48
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -27.718 -115.438 -86.797 -56.839 -29.465
Cash From Operating Activities -30.134 -83.729 -60.802 -40.363 -21.895
Cash From Operating Activities 0.278 1.324 0.962 0.625 0.307
Non-Cash Items 6.242 29.453 23.35 15.483 7.988
Changes in Working Capital -8.936 0.932 1.683 0.368 -0.725
Cash From Investing Activities 17.999 81.691 80.336 58.729 41.548
Capital Expenditures -0.81 -3.019 -2.626 -1.71 -0.952
Cash From Financing Activities -0.269 0.815 0.66 0.512 0.153
Issuance (Retirement) of Stock, Net 0.028 0.815 0.66 0.512 0.153
Issuance (Retirement) of Debt, Net
Net Change in Cash -12.404 -1.223 20.194 18.878 19.806
Other Investing Cash Flow Items, Total 18.809 84.71 82.962 60.439 42.5
Financing Cash Flow Items -0.297 0

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Prelude Therapeutics Incorporated Company profile

About Prelude Therapeutics Inc

Prelude Therapeutics Inc. is a clinical-stage precision oncology company. The Company is focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers. Its drug discovery engine is designed to identify biological targets and create new chemical entities (NCEs). Its pipeline includes six programs, including methyltransferases, kinases, protein-protein interactions and targeted protein degraders. The Company is developing therapies in both solid tumors and hematological malignancies, such as adenoid cystic carcinoma (ACC), homologous recombination deficient positive (HRD+), cancers, myelofibrosis (MF) and glioblastoma multiforme (GBM), amongst others. The Company’s product candidates include PRT543, PRT811, PRT1419, PRT2527, PRT-SCA2 and PRT-K4.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Prelude Therapeutics Inc revenues was not reported. Net loss increased 96% to $111.7M. Higher net loss reflects Research and development increase of 70% to $77.3M (expense), Stock-based Compensation in SGA increase from $3M to $11.5M (expense), General and administrative - Balancing increase from $7.6M to $15.5M (expense).

Industry: Biotechnology & Medical Research (NEC)

200 Powder Mill Road
WILMINGTON
DELAWARE 19803
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,130.90 Price
-0.800% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

ETH/USD

3,544.29 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.64 Price
+0.880% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading